查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1722414

2025 年至 2033 年潰瘍性結腸炎市場報告（按類型、疾病類型、分子類型、藥物類型、給藥途徑、配銷通路和地區分類）

Ulcerative Colitis Market Report by Type, Disease Type, Molecule Type, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 134 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球潰瘍性結腸炎市場規模達 82 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 125 億美元，2025-2033 年期間的成長率 (CAGR) 為 4.82%。由於疾病盛行率上升、醫療治療的進步以及政府的支持政策，市場正在經歷成長。此外，已開發地區和發展中地區對創新療法的全球認知不斷提高，進一步增加了市場的價值。

潰瘍性結腸炎市場分析：

主要市場促進因素：全球潰瘍性結腸炎患者數量的激增以及對發炎性腸道疾病存在的認知，刺激了患者對創新治療和診斷方法的需求。此外，技術進步、生物製劑的擴展和新療法的發明也加速了市場的發展。已開發國家和發展中國家醫療保健支出的不斷成長也促進了市場的擴大。

主要市場趨勢：潰瘍性結腸炎的治療越來越傾向於個人化醫療，強調基於遺傳、環境和表現型特徵的客製化治療方法。此外，擴大採用生物製劑和生物相似藥來治療重症病例，正在顯著影響該市場製藥業的發展方向。

地理趨勢：由於先進的醫療設施、高昂的醫療支出和成熟的製藥公司，北美在潰瘍性結腸炎市場中處於領先地位。然而，鑑於醫療設施、患者意識和以中國和印度等地區為中心的醫療旅遊業的不斷增強，亞太地區預計將以顯著的速度發展。

競爭格局：潰瘍性結腸炎產業的主要市場參與者包括雅培實驗室、艾伯維公司、阿斯特捷利康公司、百時美施貴寶公司、禮來公司、羅氏公司、葛蘭素史克公司、強生公司、默克公司、輝瑞公司、武田製藥有限公司和梯瓦製藥工業有限公司等。

挑戰與機會：市場面臨的主要挑戰是治療費用高昂，這可能會為低收入國家帶來取得治療的障礙，尤其是涉及生物製劑時。另一個因素是勞動密集且漫長的藥物核准過程，可能會延遲新療法進入市場。儘管挑戰嚴峻，挑戰也可以成為機會的基礎。開發具有成本效益的治療方法並簡化核准流程可以使全球企業受益。

潰瘍性結腸炎市場趨勢：

潰瘍性結腸炎盛行率不斷上升

潰瘍性結腸炎盛行率的成長以及人們對發炎性腸道疾病存在的認知的傳播刺激了患者對創新治療和診斷方法的需求。此外，技術進步、生物製劑的擴展以及新療法的發明也加速了市場的發展。已開發國家和發展中國家醫療保健支出的不斷成長也促進了市場的擴大。根據美國國家醫學圖書館的數據，潰瘍性結腸炎每年每十萬人的發生率為9至20例。其發生率為每年每十萬人156至291例。

醫療治療的進步

隨著生物製劑和小分子藥物的發展，潰瘍性結腸炎的醫學治療已經取得了長足的進展。這項進展所帶來的正面精神，為市場創造了更多有利因素。一方面，診斷技術的進步和新的標靶治療方法的發展對市場產生了積極影響，因為更有效的治療方法的發展推動了採用率的提高。例如，輝瑞公司於 2023 年宣布，美國食品藥物管理局 (FDA) 已批准 VELSIPITY(TM) (etrasimod)，這是一種口服、每日一次的選擇性鞘氨醇-1-磷酸 (S1P) 受體調節劑，用於治療中度至重度活動性潰瘍性結腸炎 (UC) 的成年人。

政府和監管支持

有利的政府政策和增加的醫療保健支出對潰瘍性結腸炎市場的成長產生了重大影響。隨著監管部門的批准促進新型有效藥物快速進入市場，患者可以獲得先進的治療選擇。此外，一些政府加大了研發投入，鼓勵製藥公司投資潰瘍性結腸炎的創新療法，進一步刺激了市場成長。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球潰瘍性結腸炎市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依類型

  • 輕度潰瘍性結腸炎
  • 中度潰瘍性結腸炎
  • 嚴重潰瘍性結腸炎

第7章：市場區隔：依疾病類型

  • 潰瘍性直腸炎
  • 直腸乙狀結腸炎
  • 左側結腸炎
  • 全結腸炎或普遍性結腸炎
  • 暴發性結腸炎

第8章：市場區隔：依分子類型

  • 小分子
  • 生物製劑

第9章：市場細分：依藥物類型

  • 抗發炎藥物
  • 抗TNF生物製劑
  • 免疫抑制劑
  • 鈣調神經磷酸酶抑制劑
  • 其他

第10章：市場細分：依行政途徑

  • 口服
  • 注射劑

第 11 章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 藥局
  • 其他

第12章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第 13 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 14 章：價值鏈分析

第 15 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 16 章：價格分析

第 17 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Abbott Laboratories
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A5663

The global ulcerative colitis market size reached USD 8.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 12.5 Billion by 2033, exhibiting a growth rate (CAGR) of 4.82% during 2025-2033. The market is experiencing growth due to rising disease prevalence, advancements in medical treatments, and supportive government policies. Moreover, increasing global awareness regarding innovative therapies in developed and developing regions is further adding value to the market.

Ulcerative Colitis Market Analysis:

Major Market Drivers: The surging number of ulcerative colitis globally, and the awareness about the existence of inflammatory bowel diseases, stimulate the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement.

Key Market Trends: There is an increasing trend toward personalized medicine in treating ulcerative colitis, emphasizing customized therapeutic methods based on genetic, environmental, and phenotypic characteristics. Furthermore, the increased adoption of biologics and biosimilars for managing severe cases is significantly influencing the direction of the pharmaceutical industry in this market.

Geographical Trends: North America leads the ulcerative colitis market due to advanced healthcare facilities, high healthcare expenditure, and established pharmaceutical companies. However, Asia Pacific is anticipated to develop at a significant rate, given the increased health facilities, patient awareness, and medical tourism centering the region, such as China and India.

Competitive Landscape: Some of the major market players in the ulcerative colitis industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd. among many others.

Challenges and Opportunities: The primary challenge of the market is the high cost of treatment, which may create barriers to access in low-income countries, particularly when biologics are involved. Another factor is the labor-intensive and lengthy drug approval process, which could delay new treatments from entering the market. Despite its severity, the challenge can serve as a basis for opportunities. Developing cost-effective therapies and streamlining the approval process can become beneficial for businesses across the globe.

Ulcerative Colitis Market Trends:

Increasing Prevalence of Ulcerative Colitis

The growth in the prevalence of ulcerative colitis, as well as the spread of awareness about the existence of inflammatory bowel diseases, stimulates the demand for innovative treatments and diagnostic methods among patients. In addition, technological progress, the expansion of biologics, and the invention of new therapies intensify market development. The growing expenditure on healthcare in developed and developing countries also promotes market enlargement. According to the NATIONAL LIBRARY OF MEDICINE, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year.

Advancements in Medical Treatments

Medical treatment of ulcerative colitis has come a long way with the development of biologics and small-molecule drugs. The positive spirit brought about by this progress has created more favorable market-related factors. On the one hand, advances in diagnostic technologies and the development of new targeted treatment approaches have positively affected the market due to increased adoption driven by the development of more effective treatments. For instance, Pfizer Inc. in 2023 announced that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

Government and Regulatory Support

Favorable government policies and increased healthcare spending significantly impact the ulcerative colitis market growth. With regulatory approvals facilitating the rapid market entry of new and effective drugs, patients gain access to advanced treatment options. Additionally, several governments have ramped up funding for research and development, encouraging pharmaceutical companies to invest in innovative therapies for ulcerative colitis, which further stimulates market growth.

Ulcerative Colitis Industry Segmentation:

Breakup by Type:

  • Mild UC
  • Moderate UC
  • Severe UC

Mild UC accounts for the majority of the market share

The mild ulcerative colitis segment dominates owing to the greater prevalence of mild cases compared to moderate and severe forms. Patients with mild UC generally experience fewer symptoms, which can typically be managed with oral medications, such as aminosalicylates. It benefits from numerous first-line treatment options that are less expensive and have fewer side effects, making them accessible and favored by patients and healthcare providers. The availability of effective and affordable treatments contributes significantly to the dominance of this segment in increasing the overall ulcerative colitis market demand. Mild ulcerative colitis is treated with mesalamine (5-aminosalicylic acid, 5-ASA) and other UC medications across all countries. As per the American College of Gastroenterology (ACG) treatment instruction, ulcerative colitis (UC) is categorized as mild in patients who have fewer than four (4) bowel movements per day, minimal bleeding, and no appreciable urgency or abdominal pain. In comparative studies of 2.4 g and 4.8 g daily doses of mesalamine, it was found that patients with mild disease will improve with 2.4 g and 4.8 g doses of mesalamine.

Breakup by Disease Type:

  • Ulcerative Proctitis
  • Proctosigmoiditis
  • Left-sided Colitis
  • Pancolitis or Universal Colitis
  • Fulminant Colitis

Ulcerative proctitis holds the largest share in the industry

Ulcerative proctitis is considered the mildest due to the inflammation being confined to the rectum. Patients usually experience such symptoms as rectal bleeding, urgency, and tenesmus. As per the study by Matthew Mutch, in Shackelford's Surgery of the Alimentary Tract, 2 Volume Set (Eighth Edition), 2019, patients with ulcerative pancolitis for more than 8 years are at higher risk of colorectal cancer, with the risk ranging from 0.5% to 1% per year. The localized nature of symptoms is why it is easier to treat the condition with medicines that require the closest interaction with the perished area rather than using more invasive and less patient-friendly systemic treatment. The focused treatment combines fewer systemic side effects, which is why patients prefer using suppositories or enemas as treatment. Facing better treatment opportunities, patients with ulcerative proctitis have a very good prognosis. Hence, the demand for quality treatments is growing.

Breakup by Molecule Type:

  • Small Molecules
  • Biologics

Biologics represents the leading market segment

Biologics represent the largest segment in the market. The key reasons for the popularity of this therapy type involve its high efficiency in reducing inflammation and achieving and maintaining remission in patients suffering from moderate to severe disease. These protein-containing drugs work by aiming at particular parts of the immune system that encourage developing inflammation in the body. The increasing demand for biologics is explained by the growing number of approvals and biosimilars, which will make these drugs more available and less costly. For illustration purposes, in March 2024, Johnson & Johnson unveiled the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration pursuing approval of TREMFYA(R) (guselkumab) to treat adult patients with moderately to severely active ulcerative colitis. It is supported by data from the Phase 3 QUASAR program evaluating the efficacy and safety of TREMFYA(R) to treat patients with moderately to severely active UC who had an inadequate response or intolerance to traditional therapy, prior biologics and/or JAK inhibitors.

Breakup by Drug Type:

  • Anti-Inflammatory Drugs
  • Anti-TNF Biologics
  • Immunosuppressant
  • Calcineurin Inhibitors
  • Others

Anti-TNF biologics exhibits a clear dominance in the market

The market is currently dominated by anti-TNF biologics, primarily due to their ability to control inflammation and sustain remission in patients with moderate-to-severe conditions. Anti-TNF biologics are accustomed to neutralizing the action of a protein in the body known as TNF that causes inflammation, making them a preferable option for patients who are not treated with monotherapy. In addition, the established success of anti-TNF biologics in patient quality of life would agree with these results, despite concerns about costs and side effects.

Breakup by Route of Administration:

  • Oral
  • Injectable

Injectable dominates the market

Injectable medications hold a prominent position in the ulcerative colitis market revenue, primarily due to their capacity to deliver treatments directly to the bloodstream, effectively bypassing the digestive system. This category includes biologics such as infliximab and adalimumab, which are particularly used for moderate to severe cases. The preference for injectables stems from their rapid action and high efficacy, especially beneficial for patients who do not respond to oral medications. Additionally, the less frequent dosing requirement compared to oral medications enhances the appeal of injectables, making them a popular choice in managing ulcerative colitis and contributing to their substantial market share. Top of FormFor instance, in 2023, the Food and Drug Administration (FDA) indicated that the subcutaneous administration of vedolizumab is an approvable maintenance therapy for moderate to severe ulcerative colitis following intravenous infusion. It is the only FDA-approved biologic in ulcerative colitis maintenance therapy that is based on IV and SC dose-approved medication.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Store
  • Others

Hospital pharmacies are the predominant market segment

Hospital pharmacies constitute the largest segment in the ulcerative colitis market forecast. Their pivotal role in distributing treatments stems from their proximity to patient care settings and their responsibilities in administering and monitoring therapies. Hospitals are often the first to receive new drug approvals, positioning them as primary channels for distributing advanced therapeutics. This segment benefits from direct interactions with pharmaceutical manufacturers and often engages in price negotiations, which can significantly influence treatment accessibility and adoption rates among patients. For instance, the Apollo Hospital pharmacy business is about to touch 10,000 crore in revenue this year with 5,790 pharmacies, Apollo is the largest pharmacy chain, adding 400-500 stores each year.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest ulcerative colitis market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America dominates the ulcerative colitis market on account of the high occurrence of the disorder, superior medical facilities, and extensive funding for R&D activities. The American and Canadian health systems ensure the substantial usage of progressive treatments, and private insurance plans and campaigns further enhance the consumer understanding of products. Companies in the pharmaceutical and biotech sectors accelerate the development of innovative treatment methods. They integrate the most successful ones into their treatment protocols at an early stage, advancing the market. At present, ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year and 156 to 291 cases per 100,000 persons per year as per National Institute of Health (NIH). Ulcerative colitis market recent opportunities include numerous key players collaborating to expand their market growth. For instance, Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceuticals Industries Ltd., and Sanofi collaborated to create and co-commercialize asset TEV'574, to treat Ulcerative Colitis and Crohn's Disease.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the keyword industry include Abbott Laboratories, AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Leading players in the ulcerative colitis market recent developments include the development of advanced biologics and small molecule therapies, improved drug delivery systems, and expansion into untapped markets. The leading players are also involved in strategic initiatives such as partnerships, mergers, acquisitions, and increasing investment in research and innovation to enhance treatment efficacies. These efforts are aimed at boosting market share and addressing the unmet needs in ulcerative colitis management. Besides this, Pfizer Inc. unveiled that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for VELSIPITY(TM) (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator. This medication is intended for the treatment of patients aged 16 and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biological agent.

Latest News:

November 2021: Bristol Myers Squibb received European Commission approval for Zeposia (ozanimod) for the treatment of adults with moderately to severely active ulcerative colitis.Top of Form

March 2024: AbbVie Inc., and Landos Biopharma Inc. unveiled that AbbVie entered into a definitive agreement that provides for the acquisition of Landos, a clinical-stage biopharmaceutical corporation keen on developing advanced novel oral therapeutics for individuals with autoimmune disorders.

Key Questions Answered in This Report

  • 1.How big is the ulcerative colitis market?
  • 2.What is the future outlook of ulcerative colitis market?
  • 3.What are the key factors driving the ulcerative colitis market?
  • 4.Which region accounts for the largest ulcerative colitis market share?
  • 5.Which are the leading companies in the global ulcerative colitis market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ulcerative Colitis Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Mild UC
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Moderate UC
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Severe UC
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Ulcerative Proctitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Proctosigmoiditis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Left-sided Colitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pancolitis or Universal Colitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Fulminant Colitis
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Molecule Type

  • 8.1 Small Molecules
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Biologics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Drug Type

  • 9.1 Anti-Inflammatory Drugs
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Anti-TNF Biologics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Immunosuppressant
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Calcineurin Inhibitors
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Route of Administration

  • 10.1 Oral
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Injectable
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast

11 Market Breakup by Distribution Channel

  • 11.1 Hospital Pharmacies
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Retail Pharmacies
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Drug Store
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast
  • 11.4 Others
    • 11.4.1 Market Trends
    • 11.4.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 SWOT Analysis

  • 13.1 Overview
  • 13.2 Strengths
  • 13.3 Weaknesses
  • 13.4 Opportunities
  • 13.5 Threats

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 Abbott Laboratories
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 AbbVie Inc.
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
      • 17.3.2.4 SWOT Analysis
    • 17.3.3 AstraZeneca plc
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
      • 17.3.3.3 Financials
      • 17.3.3.4 SWOT Analysis
    • 17.3.4 Bristol-Myers Squibb Company
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio
      • 17.3.4.3 Financials
      • 17.3.4.4 SWOT Analysis
    • 17.3.5 Eli Lilly and Company
      • 17.3.5.1 Company Overview
      • 17.3.5.2 Product Portfolio
      • 17.3.5.3 Financials
      • 17.3.5.4 SWOT Analysis
    • 17.3.6 F. Hoffmann-La Roche Ltd.
      • 17.3.6.1 Company Overview
      • 17.3.6.2 Product Portfolio
      • 17.3.6.3 Financials
    • 17.3.7 GlaxoSmithKline plc
      • 17.3.7.1 Company Overview
      • 17.3.7.2 Product Portfolio
      • 17.3.7.3 Financials
      • 17.3.7.4 SWOT Analysis
    • 17.3.8 Johnson & Johnson
      • 17.3.8.1 Company Overview
      • 17.3.8.2 Product Portfolio
      • 17.3.8.3 Financials
      • 17.3.8.4 SWOT Analysis
    • 17.3.9 Merck & Co. Inc.
      • 17.3.9.1 Company Overview
      • 17.3.9.2 Product Portfolio
      • 17.3.9.3 Financials
      • 17.3.9.4 SWOT Analysis
    • 17.3.10 Pfizer Inc.
      • 17.3.10.1 Company Overview
      • 17.3.10.2 Product Portfolio
      • 17.3.10.3 Financials
      • 17.3.10.4 SWOT Analysis
    • 17.3.11 Takeda Pharmaceutical Company Limited
      • 17.3.11.1 Company Overview
      • 17.3.11.2 Product Portfolio
      • 17.3.11.3 Financials
      • 17.3.11.4 SWOT Analysis
    • 17.3.12 Teva Pharmaceutical Industries Ltd.
      • 17.3.12.1 Company Overview
      • 17.3.12.2 Product Portfolio
      • 17.3.12.3 Financials
      • 17.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Ulcerative Colitis Market: Major Drivers and Challenges
  • Figure 2: Global: Ulcerative Colitis Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Ulcerative Colitis Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Ulcerative Colitis Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Ulcerative Colitis Market: Breakup by Disease Type (in %), 2024
  • Figure 6: Global: Ulcerative Colitis Market: Breakup by Molecule Type (in %), 2024
  • Figure 7: Global: Ulcerative Colitis Market: Breakup by Drug Type (in %), 2024
  • Figure 8: Global: Ulcerative Colitis Market: Breakup by Route of Administration (in %), 2024
  • Figure 9: Global: Ulcerative Colitis Market: Breakup by Distribution Channel (in %), 2024
  • Figure 10: Global: Ulcerative Colitis Market: Breakup by Region (in %), 2024
  • Figure 11: Global: Ulcerative Colitis (Mild UC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Ulcerative Colitis (Mild UC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Ulcerative Colitis (Moderate UC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Ulcerative Colitis (Moderate UC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Ulcerative Colitis (Severe UC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Ulcerative Colitis (Severe UC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Ulcerative Colitis (Ulcerative Proctitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Ulcerative Colitis (Ulcerative Proctitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Ulcerative Colitis (Proctosigmoiditis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Ulcerative Colitis (Proctosigmoiditis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Ulcerative Colitis (Left-sided Colitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Ulcerative Colitis (Left-sided Colitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Ulcerative Colitis (Pancolitis or Universal Colitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Ulcerative Colitis (Fulminant Colitis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Ulcerative Colitis (Fulminant Colitis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Ulcerative Colitis (Small Molecules) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Ulcerative Colitis (Small Molecules) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Ulcerative Colitis (Biologics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Ulcerative Colitis (Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Ulcerative Colitis (Anti-Inflammatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Ulcerative Colitis (Anti-TNF Biologics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Ulcerative Colitis (Anti-TNF Biologics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Ulcerative Colitis (Immunosuppressant) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Ulcerative Colitis (Immunosuppressant) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Ulcerative Colitis (Calcineurin Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Ulcerative Colitis (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Ulcerative Colitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Ulcerative Colitis (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Ulcerative Colitis (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Ulcerative Colitis (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Ulcerative Colitis (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Ulcerative Colitis (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Ulcerative Colitis (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Global: Ulcerative Colitis (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Global: Ulcerative Colitis (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Global: Ulcerative Colitis (Drug Store) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Global: Ulcerative Colitis (Drug Store) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Global: Ulcerative Colitis (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Global: Ulcerative Colitis (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: North America: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: North America: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: United States: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: United States: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Canada: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Canada: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Asia-Pacific: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Asia-Pacific: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: China: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: China: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Japan: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Japan: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: India: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: India: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: South Korea: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: South Korea: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Australia: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Australia: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Indonesia: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Indonesia: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Europe: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Europe: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Germany: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Germany: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: France: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: France: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: United Kingdom: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: United Kingdom: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Italy: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Italy: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Spain: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Spain: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Russia: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Russia: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Latin America: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Latin America: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Brazil: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Brazil: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 95: Mexico: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 96: Mexico: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 97: Others: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 98: Others: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 99: Middle East and Africa: Ulcerative Colitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 100: Middle East and Africa: Ulcerative Colitis Market: Breakup by Country (in %), 2024
  • Figure 101: Middle East and Africa: Ulcerative Colitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 102: Global: Ulcerative Colitis Industry: SWOT Analysis
  • Figure 103: Global: Ulcerative Colitis Industry: Value Chain Analysis
  • Figure 104: Global: Ulcerative Colitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ulcerative Colitis Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Ulcerative Colitis Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Ulcerative Colitis Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Ulcerative Colitis Market Forecast: Breakup by Molecule Type (in Million USD), 2025-2033
  • Table 5: Global: Ulcerative Colitis Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 6: Global: Ulcerative Colitis Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 7: Global: Ulcerative Colitis Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 8: Global: Ulcerative Colitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 9: Global: Ulcerative Colitis Market: Competitive Structure
  • Table 10: Global: Ulcerative Colitis Market: Key Players